OncoMatch/Clinical Trials/NCT05696782
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Is NCT05696782 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Durvalumab for nonsmall cell lung cancer stage iii.
Treatment: Durvalumab — This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR exon 19 deletion
Excluded: EGFR l858r
Disease stage
Required: Stage II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — definitive
Platinum-based chemotherapy for lung cancer that is either (a) planned to start within the next 28 days, (b) currently being administered, or (c) has been completed within the last 14 days. Chemotherapy must be for at least two cycles and be administered either before radiation therapy ("induction" or "sequential") or during radiation therapy ("concurrent").
Must have received: radiation therapy — definitive
definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions) for lung cancer that is either (a) planned to start within the next 28 days, or (b) currently being administered, or (c) has been completed within the last 14 days.
Cannot have received: immune checkpoint inhibitor
Prior exposure to an immune checkpoint inhibitor targeting CTLA-4, PD-1, or PD-L1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify